Microbiological quality control of non-sterile compounded medicines prepared in a Portuguese hospital centre

Objectives This work aimed to evaluate the quality of non-sterile formulations compounded at Centro Hospitalar Cova da Beira (Covilhã, Portugal) immediately after preparation and up to the defined ‘beyond-use date’. Methods Microbiological quality control tests were performed in accordance with monograph 5.1.4 of the European Pharmacopoeia 8.0. Samples of compounded products were collected from January to December 2014 after preparation and were analysed immediately and reanalysed after storage under the established conditions, for each preparation. Results In the test period, 392 preparations were analysed, corresponding to 24 different formulations (8 intermediate preparations, 11 oral solutions/suspensions and 5 topical preparations). All preparations were in accordance with the pharmacopoeia specifications immediately after preparation. However, for the formulations ‘prednisolone oral solution (5 mg/mL)’ and ‘nitroglycerine and cinchocaine ointment (0.25%/0.5%)’, the microbial counts of some batches exceeded the defined limits after storage up to the beyond-use date. Conclusions These results show that the compounding practices implemented at this pharmacy department are able to ensure the microbiological quality of compounded products. This microbiological quality control methodology also allowed identification of the need to replace formulations shown not to be stable throughout the storage period. On the basis of these results, a monthly routine of microbiological control of a random sample of compounded medicines was established in order to ensure their quality and safety for use.

[1]  J. Martinez-de-Oliveira,et al.  Pharmaceutical Compounding in Portuguese Community Pharmacies: CHARACTERIZATION AND FUTURE PERSPECTIVES. , 2016, International journal of pharmaceutical compounding.

[2]  Christian Hartman,et al.  Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm. , 2013, Chest.

[3]  M. Jozwiakowski,et al.  Potential Risks of Pharmacy Compounding , 2013, Drugs in R&D.

[4]  J. Breitkreutz,et al.  Preparation of medicines for children - a hierarchy of classification. , 2012, International journal of pharmaceutics.

[5]  A. Haywood,et al.  Book Review. Handbook of extemporaneous preparation. Jackson M, Lowey A. , 2011 .

[6]  A. McLachlan,et al.  Community pharmacy compounding–impact on professional status , 2011, International Journal of Clinical Pharmacy.

[7]  V. Mugoyela,et al.  Microbial contamination of nonsterile pharmaceuticals in public hospital settings , 2010, Therapeutics and clinical risk management.

[8]  M. Jackson,et al.  Handbook of Extemporaneous Preparation , 2010 .

[9]  M. Jackson,et al.  Comprar Handbook of Extemporaneous Preparation A Guide to Pharmaceutical Compounding | Mark Jackson | 9780853699019 | Pharmaceutical Press , 2010 .

[10]  L. McDonald,et al.  A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  P. Long,et al.  Poor Preservation Efficacy Versus Quality and Safety of Pediatric Extemporaneous Liquids , 2007, The Annals of pharmacotherapy.

[12]  T. McPherson,et al.  Prevalence of compounding in independent community pharmacy practice. , 2006, Journal of the American Pharmacists Association : JAPhA.

[13]  Loyd V Allen,et al.  Contemporary Pharmaceutical Compounding , 2003, The Annals of pharmacotherapy.